Kane Biotech Inc. (KNBIF)
USD 0.06
(0.0%)
USD 0.06
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 7.52 Million CAD | 47.95% |
| 2022 | 5.75 Million CAD | 61.49% |
| 2021 | 3.56 Million CAD | 186.78% |
| 2020 | 1.24 Million CAD | 286.96% |
| 2019 | -664.31 Thousand CAD | -256.47% |
| 2018 | 424.57 Thousand CAD | 121.49% |
| 2017 | -1.97 Million CAD | -661.15% |
| 2016 | -259.57 Thousand CAD | -180.53% |
| 2015 | 322.33 Thousand CAD | 162.27% |
| 2014 | -517.66 Thousand CAD | -134.03% |
| 2013 | -221.19 Thousand CAD | 84.37% |
| 2012 | -1.41 Million CAD | -7.25% |
| 2011 | -1.31 Million CAD | -603.59% |
| 2010 | -187.52 Thousand CAD | 76.7% |
| 2009 | -804.91 Thousand CAD | -46.62% |
| 2008 | -548.98 Thousand CAD | -59.35% |
| 2007 | -344.51 Thousand CAD | 50.03% |
| 2006 | -689.39 Thousand CAD | -80.47% |
| 2005 | -381.99 Thousand CAD | -38.39% |
| 2004 | -276.03 Thousand CAD | 66.52% |
| 2003 | -824.42 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 8.37 Million CAD | -0.35% |
| 2024 Q2 | 1.37 Million CAD | -83.56% |
| 2023 Q4 | 8.39 Million CAD | 10.97% |
| 2023 Q3 | 7.56 Million CAD | 9.7% |
| 2023 Q1 | 6.93 Million CAD | 20.63% |
| 2023 FY | 8.46 Million CAD | 47.12% |
| 2023 Q2 | 6.89 Million CAD | -0.55% |
| 2022 Q2 | 4.19 Million CAD | 5.08% |
| 2022 FY | 5.75 Million CAD | 61.49% |
| 2022 Q1 | 3.98 Million CAD | 12.0% |
| 2022 Q3 | 5.48 Million CAD | 30.95% |
| 2022 Q4 | 5.75 Million CAD | 4.79% |
| 2021 FY | 3.56 Million CAD | 186.78% |
| 2021 Q2 | 3.04 Million CAD | 93.7% |
| 2021 Q3 | 3.35 Million CAD | 10.05% |
| 2021 Q4 | 3.56 Million CAD | 6.12% |
| 2021 Q1 | 1.57 Million CAD | 26.77% |
| 2020 FY | 1.24 Million CAD | 286.96% |
| 2020 Q1 | -119.33 Thousand CAD | 82.04% |
| 2020 Q2 | 298.4 Thousand CAD | 350.06% |
| 2020 Q3 | -525.81 Thousand CAD | -276.21% |
| 2020 Q4 | 1.24 Million CAD | 336.2% |
| 2019 Q1 | 377.21 Thousand CAD | -11.16% |
| 2019 FY | -664.31 Thousand CAD | -256.47% |
| 2019 Q3 | 306.04 Thousand CAD | 136.91% |
| 2019 Q2 | -829.27 Thousand CAD | -319.84% |
| 2019 Q4 | -664.31 Thousand CAD | -317.06% |
| 2018 Q3 | 378.47 Thousand CAD | 210.61% |
| 2018 Q2 | -342.15 Thousand CAD | 72.51% |
| 2018 FY | 424.57 Thousand CAD | 121.49% |
| 2018 Q4 | 424.57 Thousand CAD | 12.18% |
| 2018 Q1 | -1.24 Million CAD | 36.99% |
| 2017 Q2 | 656.53 Thousand CAD | 849.29% |
| 2017 Q1 | -87.62 Thousand CAD | 66.24% |
| 2017 Q4 | -1.97 Million CAD | 21.82% |
| 2017 FY | -1.97 Million CAD | -661.15% |
| 2017 Q3 | -2.52 Million CAD | -484.94% |
| 2016 Q2 | -1.55 Million CAD | -447.19% |
| 2016 FY | -259.57 Thousand CAD | -180.53% |
| 2016 Q1 | 448.36 Thousand CAD | 39.1% |
| 2016 Q4 | -259.57 Thousand CAD | 71.65% |
| 2016 Q3 | -915.73 Thousand CAD | 41.17% |
| 2015 Q2 | 227.63 Thousand CAD | 341.95% |
| 2015 Q1 | -94.08 Thousand CAD | 81.83% |
| 2015 Q3 | 279.36 Thousand CAD | 22.72% |
| 2015 Q4 | 322.33 Thousand CAD | 15.38% |
| 2015 FY | 322.33 Thousand CAD | 162.27% |
| 2014 Q3 | 215 Thousand CAD | 1341.53% |
| 2014 Q4 | -517.66 Thousand CAD | -340.76% |
| 2014 Q1 | -387.07 Thousand CAD | -74.99% |
| 2014 FY | -517.66 Thousand CAD | -134.03% |
| 2014 Q2 | -17.31 Thousand CAD | 95.53% |
| 2013 Q1 | -1 Million CAD | 29.08% |
| 2013 FY | -221.19 Thousand CAD | 84.37% |
| 2013 Q4 | -221.19 Thousand CAD | 39.8% |
| 2013 Q3 | -367.45 Thousand CAD | 45.35% |
| 2013 Q2 | -672.36 Thousand CAD | 33.0% |
| 2012 Q2 | -728.85 Thousand CAD | 24.36% |
| 2012 Q1 | -963.54 Thousand CAD | 26.97% |
| 2012 FY | -1.41 Million CAD | -7.25% |
| 2012 Q4 | -1.41 Million CAD | -243.08% |
| 2012 Q3 | -412.44 Thousand CAD | 43.41% |
| 2011 Q2 | -1.9 Million CAD | -1880.81% |
| 2011 Q1 | -96.1 Thousand CAD | 48.75% |
| 2011 Q4 | -1.31 Million CAD | 18.24% |
| 2011 FY | -1.31 Million CAD | -603.59% |
| 2011 Q3 | -1.61 Million CAD | 15.23% |
| 2010 Q4 | -187.52 Thousand CAD | -13.17% |
| 2010 Q2 | -419.95 Thousand CAD | 26.1% |
| 2010 FY | -187.52 Thousand CAD | 76.7% |
| 2010 Q3 | -165.69 Thousand CAD | 60.54% |
| 2010 Q1 | -568.25 Thousand CAD | 29.4% |
| 2009 Q1 | -351.23 Thousand CAD | 36.02% |
| 2009 FY | -804.91 Thousand CAD | -46.62% |
| 2009 Q4 | -804.91 Thousand CAD | -188.51% |
| 2009 Q3 | -278.99 Thousand CAD | 16.31% |
| 2009 Q2 | -333.37 Thousand CAD | 5.09% |
| 2008 FY | -548.98 Thousand CAD | -59.35% |
| 2008 Q4 | -548.98 Thousand CAD | 17.96% |
| 2008 Q3 | -669.17 Thousand CAD | 43.13% |
| 2008 Q2 | -1.17 Million CAD | 21.59% |
| 2008 Q1 | -1.5 Million CAD | -335.58% |
| 2007 FY | -344.51 Thousand CAD | 50.03% |
| 2007 Q1 | -477.08 Thousand CAD | 30.8% |
| 2007 Q2 | -237.92 Thousand CAD | 50.13% |
| 2007 Q3 | -549.11 Thousand CAD | -130.79% |
| 2007 Q4 | -344.51 Thousand CAD | 37.26% |
| 2006 Q2 | -1.23 Million CAD | -568.06% |
| 2006 Q1 | -184.28 Thousand CAD | 51.76% |
| 2006 FY | -689.39 Thousand CAD | -80.47% |
| 2006 Q4 | -689.39 Thousand CAD | 29.72% |
| 2006 Q3 | -980.88 Thousand CAD | 20.32% |
| 2005 Q4 | -381.99 Thousand CAD | 33.61% |
| 2005 Q1 | -1.12 Million CAD | -306.35% |
| 2005 Q2 | -809.6 Thousand CAD | 27.82% |
| 2005 FY | -381.99 Thousand CAD | -38.39% |
| 2005 Q3 | -575.34 Thousand CAD | 28.94% |
| 2004 Q1 | -719.11 Thousand CAD | 12.77% |
| 2004 Q4 | -276.03 Thousand CAD | 30.44% |
| 2004 Q3 | -396.83 Thousand CAD | 27.78% |
| 2004 Q2 | -549.48 Thousand CAD | 23.59% |
| 2004 FY | -276.03 Thousand CAD | 66.52% |
| 2003 FY | -824.42 Thousand CAD | 0.0% |
| 2003 Q4 | -824.42 Thousand CAD | 3.84% |
| 2003 Q2 | -817.91 Thousand CAD | 0.0% |
| 2003 Q3 | -857.35 Thousand CAD | -4.82% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 52.251% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -82.775% |
| SQZ Biotechnologies Company | -36.23 Million USD | 120.77% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 82.411% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 219.386% |
| Mesoblast Limited | 55.85 Million USD | 86.525% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -711.781% |
| Genus plc | 190.6 Million USD | 96.051% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -236.641% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -520.051% |
| Marizyme, Inc. | 18.56 Million USD | 59.466% |
| ContraFect Corporation | -6.02 Million USD | 224.904% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -1006.871% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -5490.299% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -551.422% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -235.68% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -36.802% |
| MultiCell Technologies, Inc. | 90.04 USD | -8359210.307% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 1125.47% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 41.861% |
| EV Biologics, Inc. | 1.36 Million USD | -450.211% |
| Q BioMed Inc. | 4.06 Million USD | -85.387% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 75.366% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -1109.376% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -646.909% |
| Biomind Labs Inc. | 711.4 Thousand USD | -958.013% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 93.145% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 41.228% |
| Skye Bioscience, Inc. | -5.72 Million USD | 231.554% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -774.955% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -5283.768% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -33.255% |
| IMV Inc. | 7.67 Million USD | 1.875% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -37785.554% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -241.816% |
| GB Sciences, Inc. | 1.74 Million USD | -330.759% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 4195.329% |
| HST Global, Inc. | 96.79 Thousand USD | -7676.103% |
| CSL Limited | 10.52 Billion USD | 99.928% |
| Halberd Corporation | 144.72 Thousand USD | -5100.851% |
| Enzolytics Inc. | 981.65 Thousand USD | -666.737% |
| Resverlogix Corp. | 6.45 Million USD | -16.675% |
| Affymax, Inc. | -5.59 Million USD | 234.478% |
| SYBLEU INC | 473.71 Thousand USD | -1488.875% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 1218.236% |
| argenx SE | -2.02 Billion USD | 100.371% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 82.671% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 116.01% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -177.881% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 185.145% |
| AVAX Technologies, Inc. | -5.9 Million USD | 227.502% |
| Zenith Capital Corp. | 10.06 Thousand USD | -74688.583% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.709% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -3655.25% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -215.449% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -4475.265% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 87.569% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -276.451% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 392.865% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1992.442% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 62.879% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 41189.218% |
| BioStem Technologies, Inc. | 4.47 Million USD | -68.307% |
| ONE Bio Corp. | 9.04 Million USD | 16.74% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -3639.912% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 574659.008% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -3549.904% |
| Agentix Corp. | 37.63 Thousand USD | -19901.39% |
| LadRx Corporation | -2.03 Million USD | 469.597% |
| Cell Source, Inc. | 9.23 Million USD | 18.471% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 36981.238% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1084.999% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1084.999% |
| NovAccess Global Inc. | 2.17 Million USD | -245.506% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -6.445% |
| Itoco Inc. | 228.3 Thousand USD | -3196.784% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -5434.803% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -51.84% |
| Kadimastem Ltd | -253.1 Thousand USD | 3073.79% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1773.023% |
| CytoDyn Inc. | 20.26 Million USD | 62.853% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 1163426.584% |
| Mobile Lads Corp. | 484.23 Thousand USD | -1454.363% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 81308.965% |
| Qrons Inc. | 351.42 Thousand USD | -2041.76% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 2.326% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 3115.272% |
| Rebus Holdings, Inc. | 305 Thousand USD | -2367.778% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -68.873% |
| International Stem Cell Corporation | 2.59 Million USD | -190.607% |
| Bioxytran, Inc. | 1.89 Million USD | -296.37% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -11959.544% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -245.12% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -119.182% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 11.999% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -874.198% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 702.138% |
| Neutra Corp. | 52.18 Thousand USD | -14322.601% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 402.399% |
| PureTech Health plc | -167.19 Million USD | 104.502% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 3173.286% |
| IXICO plc | -4.44 Million USD | 269.346% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 43.061% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 86.278% |
| CSL Limited | 10.52 Billion USD | 99.928% |
| Cellectis S.A. | -43.81 Million USD | 117.177% |